IP Library Granted Patent US 9,713,629
Granted Patent B2
US 9,713,629 · App. 14/429,511 · Granted Jul 25, 2017

Compositions and methods for treating and preventing tissue injury and disease

Inventors: Dale R. Peterson (Carlsbad, CA); Ralph-Heiko Mattern (Ramona, CA); Corey Wilson-Wirth (San Diego, CA); Kevin L. Ohashi (Jamaica Plain, MA)
Assignee: MicroVascular Tissues, Inc.
A61K35/44A61K35/12A61L27/3625A61L27/3687A61L27/3691A61L27/3834A61L27/54A61L2300/41A61L2300/412A61L2430/10A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,713,629
App. No.
14/429,511
Granted
Jul 25, 2017
Kind
B2
Abstract

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Claims (14)

1. A method of preparing a composition comprising processed microvascular tissue, wherein the composition has angiogenic or anti-inflammatory activity, the method comprising:

(a) dissociating a microvascular tissue sample obtained from a donor mammal to produce a composition comprising dissociated microvascular tissue;

(b) removing one or more tissue components from the composition produced according to (a);

(c) optionally drying, lyophilizing, or cryopreserving the composition following (b) or (d); and

(d) sterilizing the composition following (b) or (c) and/or inactivating virus present in the composition following (b) or (c);

wherein the composition resulting from (c) or (d) retains measurable angiogenic or anti-inflammatory activity;

wherein:

(i) the cells or tissue are not cultured;

(ii) the method further comprises filtering the composition;

(iii) the dissociation of (a) comprises contacting the tissue sample with one or more proteases; and

(iv) the dissociation of (a) or the removing of (b) comprises ultrasonic agitation, centrifugation, filtration, or use of a density gradient; and further wherein

(v) the one or more proteases does not comprise collagenase;

(vi) the one or more proteases comprises or consists of: collagenase type 1 and either dispase or thermolysin; or MMP 2, MMP 14 and either dispase or thermolysin; or

(vii) the microvascular tissue is adipose-derived tissue, and the ultrasonic agitation, centrifugation, filtration or use of a density gradient removes adipocytes from the composition produced according to (a).

Continuity (2)
Provisional Application 61703203 · Sep 19, 2012
Related Publication 20150231183A1 · Aug 20, 2015